Fainting Cured? Mayo’s Daring Heart Fix

Patient monitor displaying vital signs in a hospital room — Photo: Chaikom / Shutterstock

A heart procedure that burns away misfiring nerve signals is giving chronic fainting patients their lives back, and Mayo Clinic doctors are now mapping out exactly who benefits most.

Quick Take

Cardioneural ablation targets nerve clusters on the heart that trigger fainting spells and dangerously slow heartbeats.
Mayo Clinic doctors Anthony Kashou and Guru Kowlgi detail the procedure’s evolution and patient selection on the health system’s Cardiovascular CME podcast.
Case reports show the technique working even for unusual triggers, like fainting while swallowing.
Broader medical research backs strong success rates but still calls for larger, longer studies before the procedure becomes standard guideline care.

What Cardioneural Ablation Actually Does

Cardioneural ablation, also called cardioneuroablation, uses a thin catheter threaded into the heart. Doctors use it to destroy small clusters of nerve cells called ganglionated plexi. These nerve clusters can overreact and send signals that slow the heart or cause it to skip beats, leading to sudden fainting spells known as vasovagal syncope. By disabling the faulty wiring, doctors aim to stop the fainting at its source instead of just treating symptoms afterward.

Mayo Clinic’s Dr. Guru Kowlgi, a board-certified cardiologist specializing in invasive cardiac electrophysiology, has become a leading voice on this procedure. On the Mayo Clinic Cardiovascular CME podcast, he and host Dr. Anthony Kashou walk through how the hospital’s approach to picking patients has changed over time. Their episode focuses on real outcomes from Mayo’s own program, not just theory, giving other doctors a practical look at what works in daily practice.

A Patient’s Story Behind the Numbers

Mayo Clinic has shared the story of a patient named Brenda, who struggled with repeated fainting episodes before Dr. Kowlgi recommended cardioneuroablation. The procedure targeted the nerve areas causing her symptoms, and she was able to return to an active life afterward. Stories like hers explain why interest in the treatment keeps growing among both patients and cardiologists who see standard drug therapy fail.

The technique is also showing promise in stranger, harder-to-treat cases. A recent report describes a patient whose fainting was triggered specifically by swallowing, a rare condition called deglutition syncope. Doctors at Mayo Clinic, including Kashou and Kowlgi, successfully treated the patient with cardioneural ablation, expanding the list of conditions the procedure might address beyond typical vasovagal syncope.

What The Wider Research Shows

Outside Mayo Clinic, the medical literature backs up much of the enthusiasm. Multiple meta-analyses pooling data from hundreds of patients report low rates of syncope coming back after the procedure, with one large review finding freedom from fainting in the large majority of treated patients. Another pooled analysis found periprocedural complication rates under 1 percent, suggesting the surgery itself carries relatively low risk when performed by experienced teams.

Still, cardiology researchers are careful not to call the case closed. A widely cited review titled “Cardioneuroablation: Where are we at?” notes the evidence base rests mostly on small observational studies and just one randomized controlled trial, even though results have consistently pointed toward real symptom reduction. That single-center pattern is common early in a new procedure’s life, before enough hospitals adopt it to prove the results hold up everywhere.

Why Guidelines Haven’t Caught Up Yet

Major cardiology guidelines have not yet added cardioneural ablation as a standard recommended treatment. Researchers point out that the lack of large, multicenter randomized trials keeps it out of official bradyarrhythmia treatment guidelines for now, even as individual hospitals report strong results. That gap between real-world success stories and formal guideline approval is normal for newer procedures and tends to close only after years of replicated data.

For patients who have tried medication and lifestyle changes without relief, that gap matters less than the results in front of them. Mayo Clinic’s own experience, backed by growing case reports and meta-analyses, suggests cardioneural ablation offers a real option for people whose fainting spells have resisted everything else. The next few years of research will determine how widely that option gets adopted across American hospitals.